Business Wire

Probiotics for Corals Boost Resilience, Help Prevent Mortality

Share

A new study shows probiotics to be helpful protagonists in boosting coral health and preventing mortality in the face of environmental stressors, such as warming oceans and changing climate conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005016/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

KAUST Marine Scientist Dr. Raquel Peixoto administers probiotics, or Beneficial Microorganisms for Corals (BMC), to Pocillopora verrucosa coral in controlled aquarium environments. (Photo: KAUST)

Published in Science Advances, the study details research conducted by the Federal University of Rio de Janeiro, Brazil, in collaboration with the Red Sea Research Center at King Abdullah University of Science and Technology (KAUST). It is the first of its kind to show that Beneficial Microorganisms for Corals (BMC) can protect bleached corals from death, by stimulating immune processes that help them rebuild their microbiome environment and offset “post-heat stress disorder” symptoms driven by thermal stress.

The scientists created a probiotic using microbes derived from the coral itself, selecting strains with traits deemed likeliest to boost resilience. They isolated, plated and studied hundreds of bacteria strains for their potential to serve as BMCs. They inoculated two groups of corals in controlled environments—those with probiotics and those with a placebo, exposing both to the same degree of thermal stress. Probiotics increased the stability and survivorship in the algae-coral host relationship by more than 40%.

Dr. Raquel Peixoto, lead author and KAUST marine scientist, said, “Whereas all corals initially bleached and showed signs of stress, those with BMCs survived and returned to their original state, with results similar to corals that had not been exposed at all. Corals without BMCs sustained damage or died. The holistic formula equipped the corals with hearty traits for buffering and surviving heat trauma.”

Contributing author Dr. Chris Voolstra, reef genomicist and big data specialist, said, “The study is remarkable for demonstrating ‘genetic reprogramming,’ meaning, microbes prompt the coral to make beneficial changes at the genetic level rather than superimpose their functions onto the host. This is a key understanding about the mechanisms underlying coral probiotics that was not known before.”

The study received funding from the Great Barrier Reef Foundation’s Out of the Blue Box Reef Innovation Challenge, for new ideas to protect coral reefs, and was supported by the Tiffany & Co Foundation.

Great Barrier Reef Foundation Managing Director Anna Marsden said, “Pioneering science such as this provides hope for the future of the Great Barrier Reef and coral reefs globally, which are coming under increasing pressure from climate change.”

Read the full article here.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Najdat Boukarroum
Najdat.boukarroum@kaust.edu.sa

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye